Fig. 2

Cost-effectiveness acceptability curves for HIV treatment approaches in Mozambique from the A patient perspective and B health sector perspective. ARV antiretroviral drug, DALY disability-adjusted life year, GDP gross domestic product, LTFU lost to follow-up